A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-687 for the Treatment of Diabetic Macular Edema (DME)
Latest Information Update: 13 Sep 2021
At a glance
- Drugs THR 687 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Oxurion
- 08 Sep 2021 According to an Oxurion media release, data from this study will be presented at the upcoming annual meeting of the European Society of Retina Specialists 2021, by Raj K. Maturi, M.D.
- 17 Aug 2021 According to an Oxurion media release, topline data from this study published in Ophthalmology Science, the journal of the American Academy of Ophthalmology.
- 17 Aug 2021 Results presented in an Oxurion media release.